---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2025-12-17T18:30:11.306948'
end_time: '2025-12-17T18:38:21.178177'
duration_seconds: 489.87
template_file: templates/disease_pathophysiology_research.md
template_variables:
  disease_name: Type 2 Diabetes Mellitus
  mondo_id: ''
  category: Complex
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 16
---

## Question

# Disease Pathophysiology Research Template

## Target Disease
- **Disease Name:** Type 2 Diabetes Mellitus
- **MONDO ID:**  (if available)
- **Category:** Complex

## Research Objectives

Please provide a comprehensive research report on the pathophysiology of **Type 2 Diabetes Mellitus**.
Focus on the molecular and cellular mechanisms underlying disease progression.

### Required Information

#### 1. Core Pathophysiology
- What are the primary pathophysiological mechanisms?
- What molecular pathways are dysregulated?
- What cellular processes are affected?

#### 2. Key Molecular Players
- **Genes/Proteins**: Which genes are causally involved or implicated?
- **Chemical Entities**: What metabolites, drugs, or small molecules are relevant?
- **Cell Types**: Which cell types are primarily affected?
- **Anatomical Locations**: Which tissues/organs are involved?

#### 3. Biological Processes (for GO annotation)
- What biological processes (GO terms) are disrupted?
- Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

#### 4. Cellular Components
- Where in the cell do key processes occur?
- Consider: organelles, membrane compartments, extracellular space, etc.

#### 5. Disease Progression
- What is the sequence of events from initial trigger to clinical manifestation?
- Are there distinct stages or phases?

#### 6. Phenotypic Manifestations
- What are the key clinical phenotypes?
- How do they relate to the underlying mechanisms?

### Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic claims
- Prioritize recent reviews and landmark papers
- Include direct quotes where possible to support key statements

### Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with:
- Pathophysiology description
- Gene/protein annotations with ontology terms (HGNC, GO)
- Phenotype associations (HP terms)
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Evidence items with PMIDs


## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Disease Pathophysiology Research Template

## Target Disease
- **Disease Name:** Type 2 Diabetes Mellitus
- **MONDO ID:**  (if available)
- **Category:** Complex

## Research Objectives

Please provide a comprehensive research report on the pathophysiology of **Type 2 Diabetes Mellitus**.
Focus on the molecular and cellular mechanisms underlying disease progression.

### Required Information

#### 1. Core Pathophysiology
- What are the primary pathophysiological mechanisms?
- What molecular pathways are dysregulated?
- What cellular processes are affected?

#### 2. Key Molecular Players
- **Genes/Proteins**: Which genes are causally involved or implicated?
- **Chemical Entities**: What metabolites, drugs, or small molecules are relevant?
- **Cell Types**: Which cell types are primarily affected?
- **Anatomical Locations**: Which tissues/organs are involved?

#### 3. Biological Processes (for GO annotation)
- What biological processes (GO terms) are disrupted?
- Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

#### 4. Cellular Components
- Where in the cell do key processes occur?
- Consider: organelles, membrane compartments, extracellular space, etc.

#### 5. Disease Progression
- What is the sequence of events from initial trigger to clinical manifestation?
- Are there distinct stages or phases?

#### 6. Phenotypic Manifestations
- What are the key clinical phenotypes?
- How do they relate to the underlying mechanisms?

### Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic claims
- Prioritize recent reviews and landmark papers
- Include direct quotes where possible to support key statements

### Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with:
- Pathophysiology description
- Gene/protein annotations with ontology terms (HGNC, GO)
- Phenotype associations (HP terms)
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Evidence items with PMIDs


# Disease Pathophysiology Research Report

Target Disease
- Disease Name: Type 2 Diabetes Mellitus (T2DM)
- MONDO ID: MONDO:0005148
- Category: Complex

Pathophysiology description (current understanding, 2023–2024 focus)
T2DM arises from the convergence of peripheral insulin resistance (IR) in liver, skeletal muscle, and adipose tissue with progressive pancreatic β-cell dysfunction. IR is driven by intracellular lipid intermediates (diacylglycerols, ceramides) that activate protein kinase C isoforms and promote inhibitory serine phosphorylation of IRS proteins, blunting PI3K–AKT signaling in insulin-responsive tissues, together with inflammation, adipokine imbalance, ER stress, and mitochondrial dysfunction (reviewed mechanistically by Chandrasekaran & Weiskirchen 2024; journal page provides overview of INSR/IRS/PI3K/AKT and mTOR/S6K feedback nodes; https://doi.org/10.1007/s43152-024-00056-3, Feb 2024) (chandrasekaran2024cellularandmolecular pages 1-2). β-cell failure reflects glucolipotoxic stress that perturbs ER proteostasis (UPR activation and proinsulin misfolding), damages mitochondria, alters redox signaling, and can culminate in identity loss/dedifferentiation; islet amyloid polypeptide (IAPP) deposition correlates with β-cell loss in human T2DM (review synthesis 2025 with 2023–2024 literature integration; https://doi.org/10.3390/ijms26031094) (młynarska2025type2diabetes pages 16-18). Cross-tissue mitochondrial dysfunction and pathological ROS occur early in muscle, adipose, and islets and propagate via extracellular vesicle–mediated signals, disturbing mitophagy and organelle dynamics (https://doi.org/10.3390/ijms25031504, Jan 2024) (veluthakal2024mitochondrialdysfunctionoxidative pages 1-2).

Incretin biology is central to gut–islet crosstalk: GLP-1 action is relatively preserved whereas GIP action is often blunted in T2DM; dual GLP-1/GIP agonism (e.g., tirzepatide) leverages cAMP–PKA signaling to amplify glucose-dependent insulin secretion, enhance β-cell survival, and improve weight and cardiometabolic endpoints (Acta Diabetologica 2024; https://doi.org/10.1007/s00592-024-02300-6, Jun 2024) (ciardullo2024glp1gipreceptorcoagonists pages 1-2). Large-scale human genetics and integrative omics now map effector genes and pathways controlling β-cell function during oral glucose challenges; a 2024 Nature Metabolism GWAS meta-analysis of multiple OGTT-derived β-cell indices identified 55 signals at 44 loci and nominated effector genes (e.g., ACSL1, FAM46C) that modulate insulin secretion in β-cell models (https://doi.org/10.1038/s42255-024-01140-6, Oct 2024) (madsen2024geneticarchitectureof pages 1-2). The gut–liver–pancreas axis (dysbiosis, permeability, LPS/TLR4 activation; SCFA and bile-acid signaling) contributes to systemic inflammation, IR, and β-cell stress, providing mechanistic rationale for microbiome-targeted strategies (Nutrients 2025 synthesis of 2015–2024 evidence; https://doi.org/10.3390/nu17162708) (guo2025type2diabetes pages 4-5).

| Mechanism | Key molecules/genes (HGNC) | Cell types (CL IDs) | Tissues (UBERON IDs) | Representative GO processes/components | Supporting evidence (context IDs) |
|---|---|---|---|---|---|
| Peripheral insulin resistance: lipid intermediates (DAG/ceramides) → PKC activation; IRS serine phosphorylation impairing PI3K/AKT signaling | PRKCQ, IRS1; lipid intermediates: DAG, CER | Skeletal muscle cell (CL:0000187); Adipocyte (CL:0000136); Hepatocyte (CL:0000182) | Skeletal muscle organ (UBERON:0002370); Adipose tissue (UBERON:0000990); Liver (UBERON:0002107) | insulin receptor signaling pathway (GO:0008286); protein kinase C signaling (GO:0070528) | (chandrasekaran2024cellularandmolecular pages 1-2, młynarska2025type2diabetes pages 16-18) |
| Mitochondrial dysfunction & oxidative stress with mitophagy and EV-mediated inter-organ crosstalk | PINK1, PRKN, SOD2; mitophagy regulators | Pancreatic beta cell (CL:0000169); Skeletal muscle cell (CL:0000187) | Pancreas (UBERON:0001264); Skeletal muscle organ (UBERON:0002370) | mitophagy (GO:0000422); response to oxidative stress (GO:0006979) | (veluthakal2024mitochondrialdysfunctionoxidative pages 1-2, młynarska2025type2diabetes pages 16-18) |
| Incretin axis — GLP-1/GIP signaling and therapeutic co-agonism influencing β-cell function and systemic metabolism | GLP1R, GIPR | Pancreatic beta cell (CL:0000169); Enterocyte/enteroendocrine lineage (CL:0000584) | Pancreas (UBERON:0001264); Small intestine (UBERON:0002108) | cAMP-mediated signaling (GO:0019933); regulation of insulin secretion (GO:0050796) | (ciardullo2024glp1gipreceptorcoagonists pages 1-2, chandrasekaran2024cellularandmolecular pages 1-2) |
| β-cell genetic effector genes (OGTT-based GWAS) that modulate insulin secretion | ACSL1, FAM46C (candidate effector genes from BCF-GWAS) | Pancreatic beta cell (CL:0000169) | Pancreas (UBERON:0001264) | regulation of insulin secretion (GO:0050796); insulin receptor signaling (GO:0008286) | (madsen2024geneticarchitectureof pages 1-2, młynarska2025type2diabetes pages 16-18) |
| Gut–liver–pancreas crosstalk: microbiome metabolites and endotoxin-driven inflammation (SCFAs, bile acids, LPS → TLR4) affecting IR and β-cell health | TLR4, FFAR2, FFAR3 | Enterocyte (CL:0000584); Hepatocyte (CL:0000182); Pancreatic beta cell (CL:0000169) | Small intestine (UBERON:0002108); Liver (UBERON:0002107); Pancreas (UBERON:0001264) | LPS-mediated TLR4 signaling (GO:0034142); bile acid receptor signaling pathway (GO:1902653) | (guo2025type2diabetes pages 4-5, chandrasekaran2024cellularandmolecular pages 1-2) |


*Table: Compact ontology-aligned summary mapping five core T2D mechanisms to key genes, cell/tissue ontology IDs, representative GO terms, and supporting contemporary evidence for use in knowledge-base annotation.*

Core Pathophysiology
- Primary mechanisms
  - Peripheral insulin resistance via lipid-driven PKC activation and impaired INSR–IRS–PI3K–AKT signaling in muscle, adipose, and liver; aggravated by inflammatory and ER-stress signaling and mTOR/S6K negative feedback (https://doi.org/10.1007/s43152-024-00056-3) (chandrasekaran2024cellularandmolecular pages 1-2).
  - β-cell ER stress and UPR activation with proinsulin folding load; mitochondrial dysfunction/oxidative stress; progressive loss of β-cell identity; IAPP deposition correlating with β-cell loss (https://doi.org/10.3390/ijms26031094) (młynarska2025type2diabetes pages 16-18).
  - Early, tissue-spanning mitochondrial dysfunction and ROS that drive inter-organ miscommunication (EVs, disturbed mitophagy) (https://doi.org/10.3390/ijms25031504) (veluthakal2024mitochondrialdysfunctionoxidative pages 1-2).
  - Incretin axis attenuation and pharmacologic rescue with GLP-1/GIP agonism (https://doi.org/10.1007/s00592-024-02300-6) (ciardullo2024glp1gipreceptorcoagonists pages 1-2).
  - Gut–liver–pancreas crosstalk: endotoxemia (LPS→TLR4), altered SCFAs and bile-acid signaling impair insulin sensitivity and β-cell function (https://doi.org/10.3390/nu17162708) (guo2025type2diabetes pages 4-5).

- Dysregulated molecular pathways and affected cellular processes
  - Insulin receptor signaling pathway; PKC activation by DAG/ceramides; IRS serine phosphorylation; downstream GLUT4 trafficking defects (https://doi.org/10.1007/s43152-024-00056-3) (chandrasekaran2024cellularandmolecular pages 1-2).
  - ER stress/UPR arms (PERK–eIF2α/ATF4, IRE1–XBP1s, ATF6); proinsulin proteostasis strain; β-cell identity programs (review integration) (https://doi.org/10.3390/ijms26031094) (młynarska2025type2diabetes pages 16-18).
  - Mitochondrial ROS production, impaired mitophagy (PINK1–PRKN), and organelle dynamics affecting GSIS and survival (https://doi.org/10.3390/ijms25031504) (veluthakal2024mitochondrialdysfunctionoxidative pages 1-2).
  - Incretin receptor (GLP1R, GIPR) cAMP–PKA signaling amplifying GSIS and promoting survival; system-level metabolic actions (https://doi.org/10.1007/s00592-024-02300-6) (ciardullo2024glp1gipreceptorcoagonists pages 1-2).
  - TLR4/NF-κB activation by LPS; reduced SCFA receptor (FFAR2/3) signaling; altered bile-acid (FXR/TGR5) pathways (https://doi.org/10.3390/nu17162708) (guo2025type2diabetes pages 4-5).

Key Molecular Players
- Genes/Proteins (HGNC; examples)
  - INSR, IRS1/2, PIK3R1/PIK3CA, AKT2; PRKCQ (PKC-θ); mTOR/S6K1 (https://doi.org/10.1007/s43152-024-00056-3) (chandrasekaran2024cellularandmolecular pages 1-2).
  - ER stress/UPR: EIF2AK3 (PERK), ERN1 (IRE1), ATF6; chaperones HSPA5 (BiP/GRP78); TXNIP as stress amplifier (review) (https://doi.org/10.3390/ijms26031094) (młynarska2025type2diabetes pages 16-18).
  - Mitochondria/mitophagy: PINK1, PRKN; antioxidant SOD2 (https://doi.org/10.3390/ijms25031504) (veluthakal2024mitochondrialdysfunctionoxidative pages 1-2).
  - Incretin axis: GLP1R, GIPR (https://doi.org/10.1007/s00592-024-02300-6) (ciardullo2024glp1gipreceptorcoagonists pages 1-2).
  - β-cell effector genes: ACSL1, FAM46C from OGTT-based BCF GWAS; functional silencing impacts insulin secretion (https://doi.org/10.1038/s42255-024-01140-6) (madsen2024geneticarchitectureof pages 1-2).
  - Innate/metabolic sensors: TLR4; SCFA receptors FFAR2/FFAR3 (https://doi.org/10.3390/nu17162708) (guo2025type2diabetes pages 4-5).

- Chemical entities (CHEBI; examples)
  - Diacylglycerols (DAG), ceramides (CER) as lipotoxic mediators; lipopolysaccharide (LPS); SCFAs (acetate, butyrate); bile acids (class) (mechanisms summarized) (chandrasekaran2024cellularandmolecular pages 1-2, guo2025type2diabetes pages 4-5).

- Cell types (CL)
  - Skeletal myocyte (CL:0000187), adipocyte (CL:0000136), hepatocyte (CL:0000182), pancreatic β-cell (CL:0000169), enterocyte/enteroendocrine lineage (CL:0000584) (mechanistic mapping) (chandrasekaran2024cellularandmolecular pages 1-2, ciardullo2024glp1gipreceptorcoagonists pages 1-2, guo2025type2diabetes pages 4-5).

- Anatomical locations (UBERON)
  - Skeletal muscle organ (UBERON:0002370), adipose tissue (UBERON:0000990), liver (UBERON:0002107), pancreas (UBERON:0001264), small intestine (UBERON:0002108) (chandrasekaran2024cellularandmolecular pages 1-2, ciardullo2024glp1gipreceptorcoagonists pages 1-2, guo2025type2diabetes pages 4-5).

Biological Processes (for GO annotation; examples)
- Insulin receptor signaling pathway (GO:0008286) and GLUT4 trafficking defects in IR tissues (mechanism synthesis) (chandrasekaran2024cellularandmolecular pages 1-2).
- Protein kinase C signaling (GO:0070528) downstream of DAG/ceramide (chandrasekaran2024cellularandmolecular pages 1-2).
- Unfolded protein response (GO:0030968) and ER stress signaling in β-cells (młynarska2025type2diabetes pages 16-18).
- Mitophagy (GO:0000422) and response to oxidative stress (GO:0006979) across islets and muscle (veluthakal2024mitochondrialdysfunctionoxidative pages 1-2).
- cAMP-mediated signaling (GO:0019933) and regulation of insulin secretion (GO:0050796) by GLP-1/GIP (ciardullo2024glp1gipreceptorcoagonists pages 1-2).
- LPS-mediated TLR4 signaling (GO:0034142) and bile-acid receptor signaling pathway (GO:1902653) in gut–liver axis (guo2025type2diabetes pages 4-5).

Cellular Components (where processes occur)
- Plasma membrane/lipid rafts: INSR/IRS complex; PKC localization in IR (chandrasekaran2024cellularandmolecular pages 1-2).
- Endoplasmic reticulum: proinsulin folding, UPR sensors PERK/IRE1/ATF6 (młynarska2025type2diabetes pages 16-18).
- Mitochondria: respiratory chain, ROS generation, mitophagy machinery (PINK1/PRKN) (veluthakal2024mitochondrialdysfunctionoxidative pages 1-2).
- Endosomes/secretory granules: incretin receptor trafficking; insulin granule exocytosis (ciardullo2024glp1gipreceptorcoagonists pages 1-2).
- TLR4 localization at the plasma membrane of enterocytes/hepatocytes/immune cells (guo2025type2diabetes pages 4-5).

Disease Progression (sequence of events)
1) Energy surplus, inactivity, and/or genetic risk promote ectopic lipid accumulation in muscle/liver/adipose; DAG/ceramides activate PKC and inhibit INSR–IRS–PI3K–AKT, producing tissue-specific IR with compensatory hyperinsulinemia (https://doi.org/10.1007/s43152-024-00056-3) (chandrasekaran2024cellularandmolecular pages 1-2).
2) Chronic nutrient load and inflammatory signaling induce ER stress/UPR and mitochondrial dysfunction in β-cells; redox imbalance and defective mitophagy accumulate, impairing GSIS (https://doi.org/10.3390/ijms25031504; https://doi.org/10.3390/ijms26031094) (veluthakal2024mitochondrialdysfunctionoxidative pages 1-2, młynarska2025type2diabetes pages 16-18).
3) Progressive β-cell dysfunction (reduced function/mass, dedifferentiation) fails to match IR, unmasking fasting and postprandial hyperglycemia (review synthesis; clinical trajectory) (młynarska2025type2diabetes pages 16-18).
4) Gut dysbiosis and barrier defects worsen systemic inflammation (LPS→TLR4) and metabolic signaling (reduced SCFA and altered bile-acid signaling), aggravating IR and β-cell stress (https://doi.org/10.3390/nu17162708) (guo2025type2diabetes pages 4-5).
5) Incretin defect (blunted GIP) diminishes oral-glucose insulinotropic effect; pharmacologic GLP-1/GIP agonism can restore gut–islet amplification, reduce weight, and improve cardiometabolic profiles (https://doi.org/10.1007/s00592-024-02300-6) (ciardullo2024glp1gipreceptorcoagonists pages 1-2).

Phenotypic Manifestations (selected HP terms)
- Hyperglycemia (HP:0003074), Impaired glucose tolerance (HP:0001952), Insulin resistance (HP:0000855), Hyperinsulinemia (HP:0000846), Obesity (HP:0001513). Mechanistically linked to IR and β-cell dysfunction as above (chandrasekaran2024cellularandmolecular pages 1-2, młynarska2025type2diabetes pages 16-18).

Recent developments and latest research (2023–2024 priority)
- Archetypes and early β-cell failure: Evidence that lean T2D can present with early β-cell dysfunction without marked IR; across tissues, pathological ROS and mitochondrial dysfunction emerge early and may drive progression; EV-mediated organ crosstalk is implicated (IJMS 2024; https://doi.org/10.3390/ijms25031504) (veluthakal2024mitochondrialdysfunctionoxidative pages 1-2).
- OGTT-based β-cell function genetics: GWAS meta-analysis of eight OGTT-derived β-cell traits identified 55 signals/44 loci and 92 candidate effectors; ACSL1 and FAM46C validated as regulators of insulin secretion in human β-cell models (Nature Metabolism 2024; https://doi.org/10.1038/s42255-024-01140-6) (madsen2024geneticarchitectureof pages 1-2).
- Incretin co-agonism: Dual GLP-1/GIP agonists (tirzepatide) show strong glucose-lowering and weight loss with mechanistic actions on β-cell mass/function and multiorgan metabolism (Acta Diabetologica 2024; https://doi.org/10.1007/s00592-024-02300-6) (ciardullo2024glp1gipreceptorcoagonists pages 1-2).
- Systems synthesis of IR mechanisms: Consolidated molecular map of INSR/IRS/PI3K/AKT with lipid-induced PKC activation, mTOR/S6K negative feedback, ER stress, and mitochondrial dysfunction as convergent IR pathways (2024 review; https://doi.org/10.1007/s43152-024-00056-3) (chandrasekaran2024cellularandmolecular pages 1-2).
- Gut–X axes: Integrative review outlines gut permeability/endotoxemia, BCAA/SCFA/bile-acid signaling, and neural–endocrine crosstalk linking microbiota to hepatic IR and β-cell function (Nutrients 2025; covers 2015–2024 human/animal data; https://doi.org/10.3390/nu17162708) (guo2025type2diabetes pages 4-5).

Current applications and real-world implementations
- Incretin-based therapeutics: GLP-1 receptor agonists and GLP-1/GIP co-agonists used for T2DM and obesity produce glucose-dependent insulinotropic effects, appetite suppression, and cardiometabolic benefit; mechanisms via cAMP–PKA amplifying β-cell exocytosis, anti-apoptosis, and multiorgan actions (https://doi.org/10.1007/s00592-024-02300-6) (ciardullo2024glp1gipreceptorcoagonists pages 1-2).
- Mechanism-driven stratification: Genetic variation at GLP1R and β-cell effector genes (e.g., ACSL1, FAM46C) suggests avenues for precision incretin therapy and β-cell–centric target discovery (https://doi.org/10.1038/s42255-024-01140-6) (madsen2024geneticarchitectureof pages 1-2).
- Systems targets for IR: Strategies reducing DAG/ceramide load, dampening mTOR/S6K feedback, or alleviating ER/mitochondrial stress align to the consolidated IR map (https://doi.org/10.1007/s43152-024-00056-3) (chandrasekaran2024cellularandmolecular pages 1-2).

Expert opinions and authoritative analysis
- Mechanistic IR framework (INSR–IRS–PI3K–AKT; lipid–PKC; mTOR/S6K feedback) remains the cornerstone for interpreting tissue-specific IR and for target selection (Chandrasekaran & Weiskirchen 2024) (chandrasekaran2024cellularandmolecular pages 1-2).
- Contemporary view emphasizes mitochondrial dysfunction/ROS and inter-organ miscommunication as early, unifying drivers across patient archetypes, refocusing prevention on mitochondrial quality control and oxidative signaling (Veluthakal et al., 2024) (veluthakal2024mitochondrialdysfunctionoxidative pages 1-2).
- Incretin co-agonism represents a mechanistically coherent platform therapy addressing both β-cell and whole-body energy balance (Ciardullo et al., 2024) (ciardullo2024glp1gipreceptorcoagonists pages 1-2).

Relevant statistics and data
- OGTT β-cell function GWAS: 55 independent associations at 44 loci across eight β-cell indices (~26,000 individuals), nominating 92 candidate effector genes; ACSL1/FAM46C perturbation alters insulin secretion in β-cell models (Nature Metabolism 2024) (madsen2024geneticarchitectureof pages 1-2).
- Prediabetes global burden: ~541 million adults; mitochondrial dysfunction and ROS proposed as early drivers (IJMS 2024 synthesis) (veluthakal2024mitochondrialdysfunctionoxidative pages 1-2).

Ontology-aligned annotations
- HGNC: INSR; IRS1/IRS2; PIK3CA/PIK3R1; AKT2; PRKCQ; EIF2AK3 (PERK); ERN1 (IRE1); ATF6; HSPA5; PINK1; PRKN; SOD2; GLP1R; GIPR; ACSL1; FAM46C; TLR4; FFAR2/FFAR3 (chandrasekaran2024cellularandmolecular pages 1-2, młynarska2025type2diabetes pages 16-18, veluthakal2024mitochondrialdysfunctionoxidative pages 1-2, ciardullo2024glp1gipreceptorcoagonists pages 1-2, madsen2024geneticarchitectureof pages 1-2, guo2025type2diabetes pages 4-5).
- GO Processes: insulin receptor signaling pathway (GO:0008286); protein kinase C signaling (GO:0070528); unfolded protein response (GO:0030968); response to oxidative stress (GO:0006979); mitophagy (GO:0000422); cAMP-mediated signaling (GO:0019933); regulation of insulin secretion (GO:0050796); LPS-mediated TLR4 signaling (GO:0034142); bile acid receptor signaling pathway (GO:1902653) (chandrasekaran2024cellularandmolecular pages 1-2, młynarska2025type2diabetes pages 16-18, veluthakal2024mitochondrialdysfunctionoxidative pages 1-2, ciardullo2024glp1gipreceptorcoagonists pages 1-2, guo2025type2diabetes pages 4-5).
- CL: skeletal muscle cell (CL:0000187); adipocyte (CL:0000136); hepatocyte (CL:0000182); pancreatic β-cell (CL:0000169); enterocyte/enteroendocrine (CL:0000584) (mapped in mechanisms) (chandrasekaran2024cellularandmolecular pages 1-2, ciardullo2024glp1gipreceptorcoagonists pages 1-2, guo2025type2diabetes pages 4-5).
- UBERON: skeletal muscle organ (UBERON:0002370); adipose tissue (UBERON:0000990); liver (UBERON:0002107); pancreas (UBERON:0001264); small intestine (UBERON:0002108) (chandrasekaran2024cellularandmolecular pages 1-2, ciardullo2024glp1gipreceptorcoagonists pages 1-2, guo2025type2diabetes pages 4-5).
- CHEBI: diacylglycerol (DAG); ceramide; lipopolysaccharide (LPS); acetate; butyrate; bile acids (chandrasekaran2024cellularandmolecular pages 1-2, guo2025type2diabetes pages 4-5).
- HP: Hyperglycemia (HP:0003074); Impaired glucose tolerance (HP:0001952); Insulin resistance (HP:0000855); Hyperinsulinemia (HP:0000846); Obesity (HP:0001513) (linked in clinical manifestations) (chandrasekaran2024cellularandmolecular pages 1-2, młynarska2025type2diabetes pages 16-18).

Evidence items (with URLs and publication dates)
- Chandrasekaran P, Weiskirchen R. Cellular and molecular mechanisms of insulin resistance. Current Tissue Microenvironment Reports. Feb 2024. https://doi.org/10.1007/s43152-024-00056-3 (chandrasekaran2024cellularandmolecular pages 1-2).
- Veluthakal R, et al. Mitochondrial dysfunction, oxidative stress, and inter-organ miscommunications in T2D. IJMS. Jan 2024. https://doi.org/10.3390/ijms25031504 (veluthakal2024mitochondrialdysfunctionoxidative pages 1-2).
- Madsen AL, et al. Genetic architecture of OGTT β-cell function and effector genes. Nature Metabolism. Oct 2024. https://doi.org/10.1038/s42255-024-01140-6 (madsen2024geneticarchitectureof pages 1-2).
- Ciardullo S, et al. GLP-1–GIP receptor co-agonists in T2D. Acta Diabetologica. Jun 2024. https://doi.org/10.1007/s00592-024-02300-6 (ciardullo2024glp1gipreceptorcoagonists pages 1-2).
- Guo H, et al. Type 2 diabetes and the multifaceted Gut–X axes. Nutrients. Aug 2025 (synthesizes 2015–2024 research). https://doi.org/10.3390/nu17162708 (guo2025type2diabetes pages 4-5).
- Młynarska E, et al. T2DM: new pathogenetic mechanisms. IJMS. Jan 2025 (integrates 2023–2024 findings). https://doi.org/10.3390/ijms26031094 (młynarska2025type2diabetes pages 16-18).

Therapeutic mechanistic implications
- Incretin-based therapies (GLP-1 RAs; GLP-1/GIP co-agonists) target cAMP–PKA amplification of GSIS, β-cell survival, gastric emptying, appetite circuits, and renal/cardiovascular axes—explaining observed HbA1c and weight reductions and CV risk benefits (https://doi.org/10.1007/s00592-024-02300-6) (ciardullo2024glp1gipreceptorcoagonists pages 1-2).
- IR pathway targeting: lowering lipid intermediates (DAG/ceramides), relieving mTOR/S6K negative feedback, and reducing ER/mitochondrial stress align with mechanistic maps of IR (https://doi.org/10.1007/s43152-024-00056-3) (chandrasekaran2024cellularandmolecular pages 1-2).
- Mitochondrial/oxidative stress interventions and improving mitophagy/MQC are rational to interrupt early cross-tissue drivers of disease (https://doi.org/10.3390/ijms25031504) (veluthakal2024mitochondrialdysfunctionoxidative pages 1-2).

Limitations
Some lines of evidence (e.g., direct human islet amyloid dynamics and detailed UPR arm contributions) are summarized from integrative reviews that compiled 2023–2024 studies; where possible, we prioritized peer-reviewed 2024 primary/large-scale human evidence (madsen2024geneticarchitectureof pages 1-2, chandrasekaran2024cellularandmolecular pages 1-2, ciardullo2024glp1gipreceptorcoagonists pages 1-2). (młynarska2025type2diabetes pages 16-18, veluthakal2024mitochondrialdysfunctionoxidative pages 1-2).


References

1. (chandrasekaran2024cellularandmolecular pages 1-2): Preethi Chandrasekaran and Ralf Weiskirchen. Cellular and molecular mechanisms of insulin resistance. Current Tissue Microenvironment Reports, pages 1-12, Feb 2024. URL: https://doi.org/10.1007/s43152-024-00056-3, doi:10.1007/s43152-024-00056-3. This article has 72 citations.

2. (młynarska2025type2diabetes pages 16-18): Ewelina Młynarska, Witold Czarnik, Natasza Dzieża, Weronika Jędraszak, Gabriela Majchrowicz, Filip Prusinowski, Magdalena Stabrawa, Jacek Rysz, and Beata Franczyk. Type 2 diabetes mellitus: new pathogenetic mechanisms, treatment and the most important complications. International Journal of Molecular Sciences, 26:1094, Jan 2025. URL: https://doi.org/10.3390/ijms26031094, doi:10.3390/ijms26031094. This article has 144 citations and is from a poor quality or predatory journal.

3. (veluthakal2024mitochondrialdysfunctionoxidative pages 1-2): Rajakrishnan Veluthakal, Diana Esparza, Joseph M. Hoolachan, Rekha Balakrishnan, Miwon Ahn, Eunjin Oh, Chathurani S. Jayasena, and Debbie C. Thurmond. Mitochondrial dysfunction, oxidative stress, and inter-organ miscommunications in t2d progression. International Journal of Molecular Sciences, 25:1504, Jan 2024. URL: https://doi.org/10.3390/ijms25031504, doi:10.3390/ijms25031504. This article has 53 citations and is from a poor quality or predatory journal.

4. (ciardullo2024glp1gipreceptorcoagonists pages 1-2): Stefano Ciardullo, Mario Luca Morieri, Giuseppe Daniele, Teresa Vanessa Fiorentino, Teresa Mezza, Domenico Tricò, Agostino Consoli, Stefano Del Prato, Francesco Giorgino, Salvatore Piro, Anna Solini, and Angelo Avogaro. Glp1-gip receptor co-agonists: a promising evolution in the treatment of type 2 diabetes. Acta Diabetologica, 61:941-950, Jun 2024. URL: https://doi.org/10.1007/s00592-024-02300-6, doi:10.1007/s00592-024-02300-6. This article has 17 citations and is from a peer-reviewed journal.

5. (madsen2024geneticarchitectureof pages 1-2): A. L. Madsen, S. Bonàs-Guarch, S. Gheibi, R. Prasad, J. Vangipurapu, V. Ahuja, L. R. Cataldo, O. Dwivedi, G. Hatem, G. Atla, M. Guindo-Martínez, A. M. Jørgensen, A. E. Jonsson, I. Miguel-Escalada, S. Hassan, A. Linneberg, Tarunveer S. Ahluwalia, T. Drivsholm, O. Pedersen, T. I. A. Sørensen, A. Astrup, D. Witte, P. Damm, T. D. Clausen, E. Mathiesen, T. H. Pers, R. J. F. Loos, L. Hakaste, M. Fex, N. Grarup, T. Tuomi, M. Laakso, H. Mulder, J. Ferrer, and T. Hansen. Genetic architecture of oral glucose-stimulated insulin release provides biological insights into type 2 diabetes aetiology. Nature Metabolism, 6:1897-1912, Oct 2024. URL: https://doi.org/10.1038/s42255-024-01140-6, doi:10.1038/s42255-024-01140-6. This article has 8 citations and is from a domain leading peer-reviewed journal.

6. (guo2025type2diabetes pages 4-5): Hezixian Guo, Liyi Pan, Qiuyi Wu, Linhao Wang, Zongjian Huang, Jie Wang, Li Wang, Xiang Fang, Sashuang Dong, Yanhua Zhu, and Zhenlin Liao. Type 2 diabetes and the multifaceted gut-x axes. Nutrients, 17:2708, Aug 2025. URL: https://doi.org/10.3390/nu17162708, doi:10.3390/nu17162708. This article has 2 citations and is from a poor quality or predatory journal.